# Zivo Bioscience, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Zivo Bioscience, Inc.). ## Overview Zivo Bioscience, Inc. is a U.S.-based research and development company focused on proprietary algal and bacterial strains for applications in human health, animal health, and agtech. Its business centers on developing bioactive compounds, algal biomass, and related intellectual property for therapeutic, nutritional, and functional ingredient uses. ## Products & services • Bioactive compounds from proprietary algal culture • Animal health product candidates • Human health product candidates • Algal biomass for food and nutrition ingredients • Functional ingredient applications for skin care - **Biotech product candidates** (20%) — Bioactive materials and product candidates derived from proprietary algae for human and animal health applications. - **Agtech algal biomass** (60%) — Cultivated algal biomass sold or developed for food, nutritional, and functional ingredient uses. - **Licensing and commercialization rights** (20%) — License-related economics and participation arrangements tied to ZIVO-derived bioactive ingredients. - Bioactive compounds from proprietary algal culture - Animal health product candidates - Human health product candidates - Algal biomass for food and nutrition ingredients - Functional ingredient applications for skin care ## Customers Zivo sells into two broad end markets: animal health and agtech/nutrition. On the biotech side, the company targets partners and eventual end users in poultry, dairy, companion animal, and human health applications; on the agtech side, it sells algal biomass and ingredient products into food, supplement, and skin-care channels. - **Animal health companies and producers** (primary) — Buy or license ZIVO-derived solutions for poultry coccidiosis, bovine mastitis, avian influenza, and companion animal health. - **Food and nutrition ingredient buyers** (primary) — Purchase algal biomass for use in green powders, supplements, and fortified food applications. - **Commercialization and licensing partners** (secondary) — Partner on late-stage development, regulatory work, and commercialization of bioactive compounds. - **Skin care and personal care formulators** (emerging) — Evaluate algal biomass as a functional ingredient for topical and ingestible skin health products. - Poultry health customers seeking coccidiosis solutions - Dairy producers and animal health partners for mastitis - Companion animal nutrition and joint-health buyers - Food, supplement, and functional ingredient customers - Commercial partners for late-stage development and licensing ## Geography Zivo is headquartered in the United States, while its algal biomass production is currently located in Peru. The company’s commercialization efforts are aimed at key global markets, with an initial focus on North American food and nutritional powder channels for Zivolife. - **United States** (55%) — Corporate base, R&D, and commercialization focus - **Peru** (45%) — Current algal biomass production location - United States is the corporate and development base - Peru is the production site for proprietary algal biomass - North America is an initial commercial focus for Zivolife - Global animal health markets are a target for product candidates - International partners matter for regulatory and commercialization reach ## Strategy Zivo’s strategy is to advance proprietary algae-derived compounds through regulatory, clinical, and commercial milestones while seeking partners for late-stage development and market access. In parallel, it is scaling algal biomass production and building ingredient sales around Zivolife and related nutrition applications. - **Commercialize algal biomass ingredients** (short-term) — Ingredient sales can generate nearer-term revenue while the biotech pipeline matures. - **Advance animal health product candidates** (medium-term) — Animal health indications offer a clearer path to value creation and partnering. - **Build regulatory readiness** (medium-term) — GRAS, NDI, and related approvals support broader ingredient and product commercialization. - **Secure strategic funding and partnerships** (short-term) — Development and scale-up require external capital and commercialization partners. - Advance animal and human health product candidates - Seek partners for late-stage development and commercialization - Scale Peru-based algae production toward commercial ponds - Grow ingredient sales through Zivolife and related channels - Pursue regulatory pathways such as GRAS and NDI ## Risks Zivo is exposed to development-stage biotech risk, including uncertain clinical, regulatory, and commercialization outcomes across multiple indications. It also faces funding risk because its business requires ongoing capital to support R&D, production scale-up, and partner-driven commercialization. - **Funding shortfall** [critical] — The company depends on external capital to fund operations and development. - **Regulatory and clinical failure** [high] — Product candidates require successful studies and approvals before commercialization. - **Commercialization and partner execution** [high] — The company relies on strategic partners for late-stage development and market access. - **Production scale-up risk** [medium] — Commercial algae cultivation must be scaled reliably from pilot to full production. - **Market adoption risk** [medium] — Ingredient and animal health buyers may prefer established alternatives. - Clinical and regulatory outcomes may not support commercialization - Capital needs are ongoing and external funding may be limited - Scale-up of algae production may not reach commercial economics - Partner dependence can delay or reduce monetization - Ingredient and animal health markets are competitive and regulated ## Accounting As a development-stage company, Zivo’s reported results are heavily influenced by R&D expense, stock-based compensation, and other judgment-heavy operating costs. Revenue recognition can also be important because the company has product sales, production contracts, and license-related participation arrangements that may be recognized differently depending on contract terms and delivery status. - **Revenue recognition for product sales and contracts** — Affects quarterly revenue timing and comparability - **License fee revenue share arrangements** — Affects revenue presentation and obligations - **Stock-based compensation** — Affects operating expense and loss measures - **Going-concern and liquidity assumptions** — Affects risk disclosures and valuation judgments - R&D spending is a major driver of reported losses - Stock-based compensation can materially affect operating expense - Product sales and production contracts affect revenue timing - License participation agreements may create complex revenue-sharing accounting - Going-concern and liquidity assumptions affect disclosures --- *Last updated: 2026-04-29T05:11:47.111504+00:00*